Nonalcoholic fatty liver disease and cardiovascular risk

被引：19

作者：

Misra V.L. ^{[1
]}

Khashab M. ^{[1
]}

Chalasani N. ^{[1
]}

机构：

[1] Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Clarian/IU Digestive Diseases Center, Indianapolis, IN 46202

来源：

Current Gastroenterology Reports | 2009年 / 11卷 / 1期

关键词：

Metabolic Syndrome; Bariatric Surgery; NASH; Exenatide; Rimonabant;

D O I：

10.1007/s11894-009-0008-4

中图分类号：

学科分类号：

摘要：

Nonalcoholic fatty liver disease (NAFLD) is a very common cause of chronic liver disease in the United States. A large proportion of patients with NAFLD have coexisting metabolic syndrome, a major risk factor for cardiovascular disease. A strong association between NAFLD and cardiovascular disease has been long suspected, and recent studies have confirmed that cardiovascular disease is the single most important cause of mortality in this patient population. NAFLD may pose cardiovascular risk beyond the risk conferred by traditional factors such as dyslipidemia, diabetes, and smoking. Health care providers managing patients with NAFLD should recognize this increased cardiovascular risk and should undertake early, aggressive risk factor modification. © Springer Science+Business Media, LLC 2009.

引用

页码：50 / 55

页数：5

共 53 条

[1] National Institute of Diabetes and Digestive and Kidney Diseases, Weight-control Information Network: Understanding Adult Obesity, (2008)
[2] Cheung O., Kapoor A., Puri P., Et al., The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome, Hepatology, 46, pp. 1091-1100, (2007)
[3] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, pp. 2486-2497, (2001)
[4] Galassi A., Reynolds K., He J., Metabolic syndrome and risk of cardiovascular disease: A meta-analysis, Am J Med, 119, pp. 812-819, (2006)
[5] Schwimmer J.B., Pardee P.E., Lavine J.E., Et al., Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease, Circulation, 118, pp. 277-283, (2008)
[6] Targher G., Arcaro G., Non-alcoholic fatty liver disease and increased risk of cardiovascular disease, Atherosclerosis, 191, pp. 235-240, (2007)
[7] Jeppesen J.A., Hansen T.W., Olsen M.H., Et al., C-reactive protein, insulin resistance and risk of cardiovascular disease: A population-based study, Eur J Cardiovasc Prev Rehabil, 15, pp. 594-598, (2008)
[8] Weiss R., Dziura J., Burgert T.S., Et al., Obesity and the metabolic syndrome in children and adolescents, N Engl J Med, 350, pp. 2362-2374, (2004)
[9] Hamaguchi M., Kojima T., Takeda N., Et al., The metabolic syndrome as a predictor of nonalcoholic fatty liver disease, Ann Intern Med, 143, pp. 722-728, (2005)
[10] Okosun I.S., Chandra K.M., Boev A., Et al., Abdominal adiposity in U.S. adults: Prevalence and trends, 1960-2000, Prev Med, 39, pp. 197-206, (2004)

← 1 2 3 4 5 6 →